Comment from Stephen Tsang

Summary: Dr. Stephen H. Tsang, a professor at Columbia University, supports the Haystack Project's petition for a new FDA rulemaking framework. He argues that clinical investigations for rare diseases, such as inherited retinal diseases, should be evaluated based on disease-specific contexts and "fit-for-purpose" study designs rather than traditional development paradigms.